Outlook Therapeutics Receives Nasdaq Delisting Notice for Low Bid Price

What Happened
Outlook Therapeutics, Inc. announced in an 8-K that on September 25, 2026 it received a letter from the Nasdaq Listing Qualifications Staff notifying the company that its common stock closed below the $1.00 minimum bid price required by Nasdaq Listing Rule 5550(a)(2) for 30 consecutive business days. The notification does not have an immediate effect on the listing. The company has 180 calendar days—until March 24, 2027—to regain compliance by achieving a closing bid price of at least $1.00 per share for ten consecutive business days.

Key Details

• Date of notice: September 25, 2026 (received from Nasdaq Listing Qualifications Staff).
• Deficiency: closing bid price below $1.00 for 30 consecutive business days (violates Nasdaq Rule 5550(a)(2)).
• Compliance period: 180 days, until March 24, 2027; must have $1.00+ closing price for 10 consecutive business days to cure.
• Possible next steps if not cured: may be eligible for an additional 180-day period if other initial listing standards are met and the company notifies Nasdaq (a reverse stock split is a commonly used cure); if delisting is proposed the company may appeal to a Nasdaq hearings panel.

Why It Matters
A delisting determination could reduce trading liquidity and investor access to the stock and may complicate the company’s ability to raise capital. The notice itself does not change the current listing, but investors should watch the stock’s closing price and any remedial actions (such as a reverse stock split or other measures) Outlook Therapeutics announces before the March 24, 2027 compliance date.